Pharmafile Logo
Pharmafocus logo
Advanced Search

Novartis

Showing 15 posts of 823 posts found.

Novartis

Regulators back Novartis’ Votubia

June 28, 2011
Sales and Marketing Novartis, Votubia, everolimus

Novartis’ drug Votubia has been recommended by regulators to treat a disease for which the only current option in Europe …

News
Novartis

FDA rejects Novartis’ Ilaris for gouty arthritis

June 22, 2011
Research and Development Ilaris, Novartis, gouty arthritis

An FDA advisory panel has voted against backing Novartis’ Ilaris for gouty arthritis because of safety concerns. Ilaris (canakinumab) is …

News

Novartis breaks ground on $500m Russian facility

June 21, 2011
Manufacturing and Production Novartis, Russia, pharma manufacturing news

Novartis has started construction of its new pharmaceutical manufacturing plant in St. Petersburg, Russia.The company has broken ground on the …

News
Novartis HQ

Novartis eye drug wins wider European licence

June 6, 2011
Sales and Marketing Lucentis, Novartis

Novartis’ Lucentis has been approved in Europe to treat people suffering from vision loss due to macular oedema secondary to …

News
Novartis' Afinitor (everolimus)

Novartis’ Afinitor wins landmark US approval

May 6, 2011
Sales and Marketing Afinitor, Novartis

Novartis’ Afinitor has been approved in the US for the treatment of progressive neuroendocrine tumours of pancreatic origin (PNET) in …

News
Novartis Gilenya (fingolimod)

Oral MS drug Gilenya launched in the UK

April 19, 2011
Sales and Marketing Novartis, gilenya, multiple sclerosis

Gilenya has become the first oral multiple sclerosis drug to be launched in the UK. Gilenya (fingolimod) is licenced to …

News
Novartis' Afinitor (everolimus)

NICE unimpressed with Novartis’ patient access scheme

April 19, 2011
Sales and Marketing Afinitor, Kidney cancer, NICE, Novartis

Novartis has been dealt a blow by NICE after the cost-effectiveness body finally refused to recommend, on appeal, its kidney …

News

Novartis ends phase III trial of Tasigna

April 12, 2011
GIST, Glivec, Novartis, Tasigna

Novartis has stopped a late stage study of Tasigna for certain types of stomach cancers after it failed to show …

News
Roche

Roche changes raise Novartis takeover question

March 29, 2011
Sales and Marketing Novartis, Roche, mergers and acquisitions

Roche could be vulnerable to a takeover from its Swiss rival Novartis after changes in its boardroom. The Roche family …

News
Novartis Diagnostics Filiberto de Cal

Working Life: Novartis’ Filiberto de Cal

March 25, 2011
Business Services, Sales and Marketing Novartis, Working Life, recruitment

Filiberto de Cal is director of global marketing – new products at Novartis Diagnostics. Here he outlines his route into …

News

FDA delays decision on Novartis’ COPD drug

March 23, 2011
Sales and Marketing COPD, Novartis, Onbrez Breezhaler, QAB149, bronchodilator, chronic obstructive pulmonary disease, indacterol

The FDA has delayed its licence decision on Novartis’ once-daily COPD treatment QAB149 by three months. The review process will …

News

Novartis gets FDA warning letter for Puerto Rico plant

March 21, 2011
Manufacturing and Production Ciba Vision, FDA manufacturing inspections, Novartis, SoftPerm contact lenses, manufacturing compliance, pharma manufacturing

A manufacturing facility operated by Novartis subsidiary Ciba Vision in Puerto Rico has been cited for manufacturing quality violations and …

News

Novartis plans Q2 filing for blood cancer drug

March 17, 2011
Sales and Marketing COMFORT-II trial, INC424, Incyte, JAK, Janus kinase inhibitor, Novartis, blood cancer, cancer drug, myelofibrosis, ruxolitinib

Novartis will file ruxolitinib for worldwide regulatory approval in the second quarter after the cancer drug met its primary endpoint …

News
novartis

Novartis to close UK manufacturing site, research downsized

March 16, 2011
Research and Development Horsham, Novartis, respiratory

Novartis is to close its manufacturing site in Horsham, West Sussex, but will retain its work in respiratory research at …

News
Novarits

Novartis to close UK research site

March 16, 2011
Research and Development Horsham, Novartis, job cuts, pharma job cuts

[UPDATE: Novartis has confirmed it will close its manufacturing site in Horsham, but continue to conduct respiratory research at the site …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025